<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20260929071236N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-10-05</date_registration>
      <primary_sponsor>Ardabil University of Medical Sciences</primary_sponsor>
      <public_title>Effect of Rosuvastatin on Helicobacter pylori Eradication</public_title>
      <acronym></acronym>
      <scientific_title>Evaluating the Impact of Rosuvastatin as an Adjuvant to Helicobacter pylori Eradication Regimen on Eradication Rates in Patients with Positive Helicobacter Pylori</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-11-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>208</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>https://irct.ir/trial/93757</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: The unit of randomization is the individual participant. Eligible participants will be allocated to the intervention and control groups in a 1:1 ratio. Block randomization with variable block sizes of 4 and 6 will be used. The random allocation sequence will be generated using Random Allocation Software. No stratified randomization will be used. To ensure allocation concealment, rosuvastatin and matching placebo will be packaged and labeled with numerical codes by an independent pharmacist. The allocation codes will be kept by the independent pharmacist, and individuals involved in participant enrollment and clinical care will not have access to the contents of the coded packages. The allocation codes will remain concealed until completion of the final data analysis, Blinding description: Participants, physicians and other clinical care providers, investigators, outcome assessors, and the data analyst will be blinded to participants' allocation to the intervention or control group. Rosuvastatin 20 mg and placebo without active ingredients will be prepared to be indistinguishable in appearance, color, size, and packaging. Preparation, packaging, and coding of the active drug and placebo will be performed by an independent pharmacist who will not be involved in participant enrollment, clinical care, outcome assessment, or data analysis. The medication packages will be identified only by numerical codes, and the information linking the codes to treatment allocation will be retained by the independent pharmacist. Participants, clinical care providers, investigators, and outcome assessors will not have access to the allocation code during the study. Data analysis will also be performed using coded study groups without the data analyst being aware of the assigned intervention. The allocation code will be revealed only after completion of the final data analysis.</study_design>
      <phase>3</phase>
      <hc_freetext>Helicobacter pylori infection.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Participants will receive the standard triple Helicobacter pylori eradication regimen for 14 days, consisting of oral levofloxacin 500 mg once daily, oral esomeprazole 40 mg every 12 hours, and a total of 2 g oral amoxicillin daily. In addition, they will receive oral rosuvastatin 20 mg once daily for 14 days. Intervention 2: Control group: Participants will receive the standard triple Helicobacter pylori eradication regimen for 14 days, consisting of oral levofloxacin 500 mg once daily, oral esomeprazole 40 mg every 12 hours, and a total of 2 g oral amoxicillin daily. In addition, they will receive one rosuvastatin placebo tablet daily for 14 days. The placebo will contain no active ingredient and will be matched to rosuvastatin in appearance, color, size, and packaging.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is At the time of trial registration, the final plan for sharing de-identified individual participant data has not yet been determined. The final decision will be made after considering ethical requirements, data confidentiality, informed consent provisions, and institutional and journal policies.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mahsa Mahdavirad</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Emam Khomeini Hospital, Shahid Noei Aghdam Brothers Street</address>
        <city>Ardabil</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5618985991</zip>
        <telephone>+98 45 3326 2140</telephone>
        <email>mahsa.mahdavi045@gmail.com</email>
        <affiliation>Ardabil University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Shahryar Movassagh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Emam Khomeini Hospital, Shahid Noei Aghdam Brothers Street</address>
        <city>Ardabil</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5618985991</zip>
        <telephone>+98 45 3326 2140</telephone>
        <email>shahryarmovassagh@gmail.com</email>
        <affiliation>Ardabil University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age 18 years or older
Presence of upper gastrointestinal symptoms related to Helicobacter pylori infection
Confirmed Helicobacter pylori infection based on stool antigen testing
Provision of informed consent to participate in the study</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>History of gastric surgery
History of previous Helicobacter pylori eradication therapy
Use of antibiotics, proton pump inhibitors, histamine receptor blockers, or non-steroidal anti-inflammatory drugs during the previous month
Known allergy to any of the antibiotics used in the study
Presence of gastrointestinal malignancy
Presence of gastrointestinal bleeding
Pregnancy
Breastfeeding</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>B98.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Helicobacter pylori [H.pylori] as the cause of diseases classified to other chapters</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Participants will receive the standard triple Helicobacter pylori eradication regimen for 14 days, consisting of oral levofloxacin 500 mg once daily, oral esomeprazole 40 mg every 12 hours, and a total of 2 g oral amoxicillin daily. In addition, they will receive oral rosuvastatin 20 mg once daily for 14 days.</i_keyword>
      <i_keyword>Control group: Participants will receive the standard triple Helicobacter pylori eradication regimen for 14 days, consisting of oral levofloxacin 500 mg once daily, oral esomeprazole 40 mg every 12 hours, and a total of 2 g oral amoxicillin daily. In addition, they will receive one rosuvastatin placebo tablet daily for 14 days. The placebo will contain no active ingredient and will be matched to rosuvastatin in appearance, color, size, and packaging.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Percentage of participants with successful eradication of Helicobacter pylori infection. Timepoint: One month after completion of the 14 day treatment course. Method of measurement: Helicobacter pylori stool antigen test.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Percentage of participants experiencing at least one treatment related adverse event. Timepoint: At the follow up visit one month after completion of the 14 day treatment course. Method of measurement: Face to face interview with the participant using a predefined adverse event checklist including headache, epigastric pain, nausea, diarrhea, and other unwanted symptoms.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Ardabil University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-08-26</approval_date>
        <contact_name>Research Ethics Committees of Ardabil University of Medical Sciences</contact_name>
        <contact_address>Vice-Chancellery for Research and Technology, Ardabil University of Medical Sciences, North Side of the University Administrative Complex, University Square, University Street Ardabil Ardabil Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
